<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576861</url>
  </required_header>
  <id_info>
    <org_study_id>Long-Term GH in CHF</org_study_id>
    <nct_id>NCT01576861</nct_id>
  </id_info>
  <brief_title>Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <brief_summary>
    <textblock>
      After the encouraging results of 6 months of Growth Hormone Replacement Therapy in Patients
      With Chronic Heart Failure and Coexisting Growth Hormone Deficiency (NCT00591760) the
      investigators wanted to collect data about the long-term efficacy and safety of this kind of
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Oxygen Consumption</measure>
    <time_frame>after 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Side effects</measure>
    <time_frame>Any side effects recorded after 6,24 and 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>after 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular End-Systolic Volume</measure>
    <time_frame>after 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular End-Diastolic Volume</measure>
    <time_frame>after 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>after 48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>GH replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 48 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,012 mg/kg every second day, added to their background optimized CHF therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control CHF patients under optimized CHF therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatotropin</intervention_name>
    <description>Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day</description>
    <arm_group_label>GH replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic Heart Failure New York Heart Association functional class II to IV, secondary
             to ischemic or idiopathic cardiomyopathy

          -  Age range 18-80 years

          -  Stable medication for at least one month including beta-blockers that had to be
             started at least 5 months before entering the study

          -  Left Ventricular ejection fraction 40% or less

          -  Growth Hormone Deficiency (defined as a peak GH response to intravenous stimulation
             with GHRH + Arginine &lt; 9 ng/ml)

          -  Written Informed consent

        Exclusion Criteria:

          -  Acute proliferative or severe non-proliferative diabetic retinopathy

          -  Active malignancy

          -  Evidence of progression or recurrence of an underlying intracranial tumor

          -  Unstable Angina or recent myocardial infarction

          -  Serum Creatinine levels &gt; 2.5 mg/dl

          -  Severe liver disease (Child-Pugh B-C)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Internal Medicine, Cardiovascular and Immunological Sciences</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://jcem.endojournals.org/content/94/9/3329.long</url>
    <description>preliminary short term data</description>
  </link>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2012</study_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Antonio Cittadini</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

